India, Feb. 10 -- GLP-1 drugs like Ozempic and Wegovy, for the longest time, have been thought to have benefits that are dependent on weight loss. However, a new study shows that many of its health benefits have little to do with weight loss.

On February 10, Eric Topol, a physician-scientist and founder and director of Scripps Research Translational Institute, highlighted the many benefits of GLP-1 drugs by sharing a February 9 study - 'Semaglutide ameliorates osteoarthritis progression through a weight loss-independent metabolic restoration mechanism.'

Highlighting the findings of the study, Eric wrote, "We used to think that the benefit of GLP-1 drugs (like Ozempic) was dependent on weight loss. Now we know so many health benefits hav...